Hefei Lifeon Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2026: 12.45%

Hefei Lifeon Pharmaceutical Co Ltd (003020) has an Asset Resilience Ratio of 12.45% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hefei Lifeon Pharmaceutical Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥325.58 Million

≈ $47.64 Million USD Cash + Short-term Investments

Total Assets

CN¥2.61 Billion

≈ $382.60 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Hefei Lifeon Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Hefei Lifeon Pharmaceutical Co Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Hefei Lifeon Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 003020 total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥325.58 Million	12.45%
Total Liquid Assets	CN¥325.58 Million	12.45%

Asset Resilience Insights

Moderate Liquidity: Hefei Lifeon Pharmaceutical Co Ltd has 12.45% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Hefei Lifeon Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hefei Lifeon Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Hefei Lifeon Pharmaceutical Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Hefei Lifeon Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.56%	CN¥40.27 Million ≈ $5.89 Million	CN¥2.59 Billion ≈ $378.39 Million	-0.69pp
2024-12-31	2.24%	CN¥58.00 Million ≈ $8.49 Million	CN¥2.59 Billion ≈ $378.41 Million	-0.23pp
2023-12-31	2.48%	CN¥61.52 Million ≈ $9.00 Million	CN¥2.48 Billion ≈ $363.44 Million	+2.47pp
2022-12-31	0.01%	CN¥115.39K ≈ $16.88K	CN¥2.12 Billion ≈ $310.48 Million	0.00pp
2021-12-31	0.01%	CN¥132.55K ≈ $19.40K	CN¥1.67 Billion ≈ $245.02 Million	--

pp = percentage points

About Hefei Lifeon Pharmaceutical Co Ltd

SHE:003020 China Biotechnology

Market Cap

$568.39 Million

CN¥3.88 Billion CNY

Market Cap Rank

#11689 Global

#3339 in China

Share Price

CN¥17.02

Change (1 day)

+2.04%

52-Week Range

CN¥14.66 - CN¥31.69

All Time High

CN¥38.76